Description: Celestial Biolabs Limited provides herbal, enzymes, and nutraceutical products in India. Its herbal products include granules to control stress; capsules for diarrhea, dysentery, Ibs and amoebiasis, allergic dermatitis, sinusitis, upper respiratory tract infection, fever, and cerebrovascular disease; tablets for stamina and strength; syrups, such as liver tonics, blood purifier, and digestive tonics, as well as syrups to treat gynecological disorders, cough and allergic disorders, and functional or metabolic efficiency; oils for pain and mobility; and fairness creams, as well as various ayurvedic products. The company also offers various enzyme products for use in detergent, textile, pulp and paper, poultry feed additive, grain-based distillery, molasses based distillery, sugar, and food processing industries. In addition, it provides nutraceuticals for use in GI health, antibacterial/antifungal/antithrombotic/anti-inflammatory, cancer, mental visual function, menopause, heart disease, bone health, cancer, blood sugar, antioxidant, and cardiovascular applications. The company was formerly known as Celestial Technologies Limited and changed its name to Celestial Biolabs Limited in February 2004. Celestial Biolabs Limited was incorporated in 1997 and is based in Hyderabad, India.
Home Page: www.celestialbiolabs.com
Plot No 82, Venkat Reddy Nagar
Hyderabad,
500039
India
Phone:
91 96 1888 2881
Officers
| Name | Title |
|---|---|
| Mr. Amit Kumar Singh | MD, Assistant VP & Whole Time Director |
| Mr. Arvind Deviprasad Sharma | Chief Financial Officer |
| Mr. Ashish Sharma | Admin Exec. |
| Ms. Sada Naga Latha | Company Sec. & Compliance Officer |
| Mr. R. Mathurnath | Gen. Mang. of Sales & Marketing |
| B. Krishna | Exec. Officer of Human Resource |
| Dr. G. Balakrishna | Head of Biotech Division |
| Mr. A. K. Singh | Production Mang. |
Exchange: NSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 1.0938 |
| Price-to-Book MRQ: | 0.0379 |
| Price-to-Sales TTM: | 23.254 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 20 |